Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging

Not Applicable

Completed

• Conditions: Hepatic Steatosis; Pituitary Gland Failure
• Interventions: Other: NMR; Biological: Blood samples; Other: fibroscan

• Registration Number: NCT02814240
• Lead Sponsor: Centre Hospitalier Universitaire Dijon

Brief Summary

The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03-16
• Primary Completion: 2015-10-10
• Study Completion: 2015-10-10
• Study First Submitted: 2016-06-23
• Study First Submitted QC: 2016-06-24
• Study First Posted: 2016-06-27
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-19
• Last Update Posted: 2024-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Patients who have provided consent
• Patients over 18 years
• Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary.

Exclusion Criteria

• Persons without national health insurance
• Pacemaker (Contra-Indication for MRI)
• Alcohol consumption greater than 4 glasses a day
• Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden
• Presence of metallic implants (Contra-Indication for MRI)
• Claustrophobia
• Adult under guardianship
• Pregnant or breast-feeding women
• Patients with a liver disease other than non-alcoholic steatosis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pituitary gland failure	Blood samples	-
Pituitary gland failure	fibroscan	-
Pituitary gland failure	NMR	-

Primary Outcome Measures

Name	Time	Method
Measurement of liver fat mass by Magnetic Resonance Imaging (MRI)	Measured at Day 0

Trial Locations

Locations (1)

CHU Dijon Bourgogne; 🇫🇷 Dijon, France